Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III...
Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
About this item
Full title
Author / Creator
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Subjects
More information
Scope and Contents
Contents
Background
Consolidation therapy with durvalumab after concurrent chemoradiotherapy has been reported to significantly prolong progression‐free survival and overall survival in patients with stage III unresectable non‐small cell lung cancer (NSCLC). However, which chemotherapy regimen should be selected for consolidation therapy with durvalumab...
Alternative Titles
Full title
Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_723b1abe462b4ef7a9887243f4ceee12
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_723b1abe462b4ef7a9887243f4ceee12
Other Identifiers
ISSN
1759-7706
E-ISSN
1759-7714
DOI
10.1111/1759-7714.14005
